Correct me if I am wrong, Doc, but hasn't the pps gone up since since the Statinome PR came out? It seems to me that investors have been buying it and driving the price up. I have said all along that DNAG is a high-risk penny stock with a lousy track record, but great potential. Recently, the risk has gone down a notch, IMO. The track record is still lousy and the risk is still high, and the potential keeps getting better. IMHO I think the pps will continue to rise this year as the revenues continue to rise, the risk decreases, and the products in the pipeline continue their march to market.
Virgil
News 
Market Data 
Discover 
AI
